Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.07 USD | -2.75% | -6.81% | -18.46% |
10/05 | Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating | MT |
08/05 | Transcript : Mirum Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.46% | 116.65Cr | |
+33.63% | 5.08TCr | |
-0.09% | 4.28TCr | |
+49.62% | 4.2TCr | |
-4.96% | 2.95TCr | |
+11.18% | 2.61TCr | |
-21.95% | 1.91TCr | |
+8.61% | 1.31TCr | |
+28.31% | 1.22TCr | |
+24.73% | 1.21TCr |
- Stock Market
- Equities
- MIRM Stock
- News Mirum Pharmaceuticals, Inc.
- Citigroup Starts Mirum Pharmaceuticals at Buy With $38 Price Target